These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

625 related items for PubMed ID: 31888350

  • 21. Balancing vancomycin efficacy and nephrotoxicity: should we be aiming for trough or AUC/MIC?
    Patel K, Crumby AS, Maples HD.
    Paediatr Drugs; 2015 Apr; 17(2):97-103. PubMed ID: 25644329
    [Abstract] [Full Text] [Related]

  • 22. The Impact of AUC-Based Monitoring on Pharmacist-Directed Vancomycin Dose Adjustments in Complicated Methicillin-Resistant Staphylococcus aureus Infection.
    Stoessel AM, Hale CM, Seabury RW, Miller CD, Steele JM.
    J Pharm Pract; 2019 Aug; 32(4):442-446. PubMed ID: 29554847
    [Abstract] [Full Text] [Related]

  • 23. Outcomes of a pharmacist-driven vancomycin monitoring initiative in a community hospital.
    Joseph K, Ramireddy K, Madison G, Turco T, Lui M.
    J Clin Pharm Ther; 2021 Aug; 46(4):1103-1108. PubMed ID: 33768555
    [Abstract] [Full Text] [Related]

  • 24. Pharmacokinetics of vancomycin in extremely obese patients with suspected or confirmed Staphylococcus aureus infections.
    Adane ED, Herald M, Koura F.
    Pharmacotherapy; 2015 Feb; 35(2):127-39. PubMed ID: 25644478
    [Abstract] [Full Text] [Related]

  • 25. Association Between Vancomycin Trough Concentrations and Duration of Methicillin-Resistant Staphylococcus aureus Bacteremia in Children.
    Hsu AJ, Hamdy RF, Huang Y, Olson JA, Ghobrial S, Gerber JS, Hersh AL, Tamma PD.
    J Pediatric Infect Dis Soc; 2018 Dec 03; 7(4):338-341. PubMed ID: 28992126
    [Abstract] [Full Text] [Related]

  • 26. The Influence of the Route of Antibiotic Administration, Methicillin Susceptibility, Vancomycin Duration and Serum Trough Concentration on Outcomes of Pediatric Staphylococcus aureus Bacteremic Osteoarticular Infection.
    McNeil JC, Kaplan SL, Vallejo JG.
    Pediatr Infect Dis J; 2017 Jun 03; 36(6):572-577. PubMed ID: 28027279
    [Abstract] [Full Text] [Related]

  • 27. High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity.
    Hidayat LK, Hsu DI, Quist R, Shriner KA, Wong-Beringer A.
    Arch Intern Med; 2006 Oct 23; 166(19):2138-44. PubMed ID: 17060545
    [Abstract] [Full Text] [Related]

  • 28. Empiric guideline-recommended weight-based vancomycin dosing and nephrotoxicity rates in patients with methicillin-resistant Staphylococcus aureus bacteremia: a retrospective cohort study.
    Hall RG, Hazlewood KA, Brouse SD, Giuliano CA, Haase KK, Frei CR, Forcade NA, Bell T, Bedimo RJ, Alvarez CA.
    BMC Pharmacol Toxicol; 2013 Feb 13; 14():12. PubMed ID: 23402420
    [Abstract] [Full Text] [Related]

  • 29. Relationships between vancomycin minimum inhibitory concentration, dosing strategies, and outcomes in methicillin-resistant Staphylococcus aureus bacteremia.
    Clemens EC, Chan JD, Lynch JB, Dellit TH.
    Diagn Microbiol Infect Dis; 2011 Dec 13; 71(4):408-14. PubMed ID: 21924852
    [Abstract] [Full Text] [Related]

  • 30. Impact of area under the concentration-time curve to minimum inhibitory concentration ratio on vancomycin treatment outcomes in methicillin-resistant Staphylococcus aureus bacteraemia.
    Song KH, Kim HB, Kim HS, Lee MJ, Jung Y, Kim G, Hwang JH, Kim NH, Kim M, Kim CJ, Choe PG, Chung JY, Park WB, Kim ES, Park KU, Kim NJ, Kim EC, Oh MD.
    Int J Antimicrob Agents; 2015 Dec 13; 46(6):689-95. PubMed ID: 26555059
    [Abstract] [Full Text] [Related]

  • 31. Evaluation of vancomycin population susceptibility analysis profile as a predictor of outcomes for patients with infective endocarditis due to methicillin-resistant Staphylococcus aureus.
    Casapao AM, Davis SL, McRoberts JP, Lagnf AM, Patel S, Kullar R, Levine DP, Rybak MJ.
    Antimicrob Agents Chemother; 2014 Aug 13; 58(8):4636-41. PubMed ID: 24890596
    [Abstract] [Full Text] [Related]

  • 32. Vancomycin Dosing Considerations in a Real-World Cohort of Obese and Extremely Obese Patients.
    Morrill HJ, Caffrey AR, Noh E, LaPlante KL.
    Pharmacotherapy; 2015 Sep 13; 35(9):869-75. PubMed ID: 26343549
    [Abstract] [Full Text] [Related]

  • 33. A randomized phase 2B trial of vancomycin versus daptomycin for the treatment of methicillin-resistant Staphylococcus aureus bacteremia due to isolates with high vancomycin minimum inhibitory concentrations - results of a prematurely terminated study.
    Kalimuddin S, Chan YFZ, Phillips R, Ong SP, Archuleta S, Lye DC, Tan TT, Low JGH.
    Trials; 2018 Jun 01; 19(1):305. PubMed ID: 29859132
    [Abstract] [Full Text] [Related]

  • 34. Daptomycin Improves Outcomes Regardless of Vancomycin MIC in a Propensity-Matched Analysis of Methicillin-Resistant Staphylococcus aureus Bloodstream Infections.
    Claeys KC, Zasowski EJ, Casapao AM, Lagnf AM, Nagel JL, Nguyen CT, Hallesy JA, Compton MT, Kaye KS, Levine DP, Davis SL, Rybak MJ.
    Antimicrob Agents Chemother; 2016 Oct 01; 60(10):5841-8. PubMed ID: 27431221
    [Abstract] [Full Text] [Related]

  • 35. The Emperor's New Clothes: PRospective Observational Evaluation of the Association Between Initial VancomycIn Exposure and Failure Rates Among ADult HospitalizEd Patients With Methicillin-resistant Staphylococcus aureus Bloodstream Infections (PROVIDE).
    Lodise TP, Rosenkranz SL, Finnemeyer M, Evans S, Sims M, Zervos MJ, Creech CB, Patel PC, Keefer M, Riska P, Silveira FP, Scheetz M, Wunderink RG, Rodriguez M, Schrank J, Bleasdale SC, Schultz S, Barron M, Stapleton A, Wray D, Chambers H, Fowler VG, Holland TL.
    Clin Infect Dis; 2020 Apr 10; 70(8):1536-1545. PubMed ID: 31157370
    [Abstract] [Full Text] [Related]

  • 36. Evaluation of Therapeutic Vancomycin Monitoring in Taiwan.
    Chen TT, Liu MP, Sun HC.
    Microbiol Spectr; 2022 Apr 27; 10(2):e0156221. PubMed ID: 35412391
    [Abstract] [Full Text] [Related]

  • 37. Vancomycin AUC24/MIC ratio in patients with complicated bacteremia and infective endocarditis due to methicillin-resistant Staphylococcus aureus and its association with attributable mortality during hospitalization.
    Brown J, Brown K, Forrest A.
    Antimicrob Agents Chemother; 2012 Feb 27; 56(2):634-8. PubMed ID: 22123681
    [Abstract] [Full Text] [Related]

  • 38. Attention to age: similar dosing regimens lead to different vancomycin levels among older and younger patients.
    Yahav D, Abbas M, Nassar L, Ghrayeb A, Shepshelovich D, Kurnik D, Leibovici L, Paul M.
    Age Ageing; 2019 Dec 01; 49(1):26-31. PubMed ID: 31711101
    [Abstract] [Full Text] [Related]

  • 39. Are Vancomycin Trough Concentrations of 15 to 20 mg/L Associated With Increased Attainment of an AUC/MIC ≥ 400 in Patients With Presumed MRSA Infection?
    Hale CM, Seabury RW, Steele JM, Darko W, Miller CD.
    J Pharm Pract; 2017 Jun 01; 30(3):329-335. PubMed ID: 27074786
    [Abstract] [Full Text] [Related]

  • 40. Innovative approaches to optimizing the delivery of vancomycin in individual patients.
    Pai MP, Neely M, Rodvold KA, Lodise TP.
    Adv Drug Deliv Rev; 2014 Nov 20; 77():50-7. PubMed ID: 24910345
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 32.